C-I5HIPelage Pharmaceuticals
stem cell activation, topical small molecule, metabolic switch
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-I5HI
C-I5HIC-I5HIstem cell activation, topical small molecule, metabolic switch
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Pelage Pharmaceuticals stem cell activation, topical small molecule, metabolic switch
Pelage Pharmaceuticals is developing regenerative medicines for hair loss based on stem cell biology. Its lead program, PP405, is described as a topically applied small molecule designed to reactivate dormant hair follicle stem cells without detectable systemic exposure. The company reports a Phase 2a study in androgenetic alopecia and plans progression into Phase 3 trials in 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Pelage Pharmaceuticals — Translational · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic